louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00961987: Innovation to Providing Interprofessional Maternity Care
Official title: Innovation to the Provision of Maternity Care in Hamilton: An Inter- and Intraprofessional Collaboration
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pregnancy
Keywords: Maternity care
Interprofessional collaboration
Continuity of Care
Integration
Lead sponsor: McMaster University
Sponsor class: OTHER
First posted: 2009-08-19
Enrollment: 700
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this pilot project is to determine if there are differences in patient outcomes and healthcare utilization between patients randomly assigned to usual care (a collaborative model of maternity care with co-located healthcare professionals but with referrals to off-site obstetricians) or to a collaborative model of maternity care with co-located healthcare professionals, including obstetricians. It is hypothesized that by creating a seamless interface between obstetrical consultation and ongoing longitudinal maternity care, patient outcomes (birth outcome data), patient satisfaction and healthcare utilization, including number of outpatient visits, ultrasounds, laboratory tests, consultations, etc, will be improved in the intervention group compared with the group receiving usual care. The results could potentially lead to other sites adopting this innovative model of maternity healthcare delivery.


Eligibility criteria: Inclusion Criteria:

* 16 years of age or older
* Attending their intake appointment at the Centre
* Ability to understand English
* Legal status in Canada

Exclusion Criteria:

-

Primary outcomes:
measure: Patient outcomes (birth outcomes)
timeFrame: 9 months
Secondary outcomes:
measure: Patient satisfaction
timeFrame: 9 months
measure: Healthcare utilization
timeFrame: 9 months
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: Maternity Centre
state: Ontario
Study officials:
affiliation: McMaster University
name: Keyna Bracken, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04157387: Cyriax Inferior Capsule Stretching in Idiopathic Adhesive Capsulitis
Official title: Effect of Cyriax Inferior Capsule Stretching in Idiopathic Adhesive Capsulitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adhesive Capsulitis
Keywords: Adhesive Capsulitis
Cyriax Manual Therapy
Stretching
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2019-11-08
Enrollment: 28
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of study is to find out the effectiveness of cyriax capsular stretching in idiopathic adhesive capsulitis and to find out the combined effect of capsular stretching's, mobilization and conservative treatment on pain and Range of Motion (ROM) in idiopathic adhesive capsulitis.

Detailed description: This Randomized study was carried out at Pakistan Railway Hospital Rawalpindi. A total of 28 patients were screened out as per inclusion criteria and randomly placed into two groups A and B through lottery method. The Visual Analogue scale, Shoulder Pain and Disability Index, and Range of Motion of shoulder joint were used as outcome measures. All the patients were assessed at baseline before intervention and at the completion of 3weeks of treatment.

Eligibility criteria: Inclusion Criteria:

* Idiopathic Adhesive capsulitis phase 1 and phase 2
* Follow capsular pattern ( ER \> Abduction\> IR)

Exclusion Criteria:

* Adhesive capsulitis phase 3
* Any intrinsic etiology i.e. rheumatoid arthritis,
* infection,
* gout,
* haemarthrosis or
* tumor or Arthritis in stage III or in stage II with a spastic end-feel

Primary outcomes:
measure: Goniometer
timeFrame: 3rd week
measure: Visual Analogue Scale (VAS)
timeFrame: 3rd Week
measure: Shoulder pain and disability index (SPADI)
timeFrame: 3rd week
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Riphah International university
state: Punjab
Study officials:
affiliation: Riphah International University
name: Abdul Ghafoor Sajjad, Phd*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03379987: Analgesic Efficacy of Paravertebral Morphine
Official title: Analgesic Efficacy of Paravertebral Morphine for Acute Postoperative Pain: Randomized Multicenter Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Pain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-12-20
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigator will test the analgesic efficacy of paravertebral morphine as an adjuvant to local anesthetics for acute postoperative pain following breast surgery and renal surgery


Eligibility criteria: Inclusion criteria

* Adult patients subjected to mastectomy or renal surgery

Exclusion criteria

* Patients complaining of coagulopathies
* Patients with vertebral anomalies

Primary outcomes:
measure: 24 hour postoperative morphine consumption
timeFrame: the first postoperative 24 hour
Secondary outcomes:
measure: VAS pain score (visual analogue pain score)
timeFrame: we will assess every 4 hour in the first postoperative 24 hour
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Diab
state: Assuit
Study officials:
References:
Clinical trial NCT02186587: iTotal Pilot Study of ConforMIS Custom Total Knee Implant
Official title: CT-navigated, Patient-specific Custom Total Knee Replacement Versus Standard Total Knee Replacement: Comparison With a Marker-less Gait Analysis System and Validated Outcome Scores
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Arthroplasty, Total
Lead sponsor: University of Missouri-Columbia
Sponsor class: OTHER
First posted: 2014-07-10
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To compare the outcomes of patients receiving the ConforMIS custom total knee implant to the outcomes of patients who receiving an off-the-shelf total knee implant.

Hypothesis: Patient-specific, custom total knee implants manufactured from patient CT data, and implanted with CT-navigated custom instruments will show faster functional recovery, including gait and patient functional outcome scores, when compared to standard, off-the-shelf total knee components inserted with non-navigated instruments (the present standard of care in total knee surgery).

Detailed description: The experimental design was changed based on enrollment hurdles to be a single cohort observational study where ConforMIS patients were enrolled and followed for 6 months with 6 minute walk used as the primary outcome measure.

Eligibility criteria: Inclusion Criteria:

- undergoing total knee arthroplasty

Exclusion Criteria:

- BMI \>40

Primary outcomes:
measure: Distance Measured During 6-minute Walk Test
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Columbia
country: United States
facility: Missouri Orthopaedic Institute
state: Missouri
Study officials:
affiliation: Professor - PI
name: Sonny Bal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02807987: Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment
Official title: A Study of CS-3150 to Evaluate Efficacy and Safety in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension With Moderate Renal Impairment
Keywords: Mineralocorticoid receptor antagonist
Moderate renal impairment
Hypertension
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
First posted: 2016-06-21
Enrollment: 58
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with moderate renal impairment.


Eligibility criteria: Inclusion Criteria:

* Male and female subjects aged 20 or order to 80 or younger years at informed consent
* Subjects with hypertension (Sitting SBP ≥ 140 mmHg, \<180 mmHg and Sitting DBP ≥ 80 mmHg, \<110 mmHg
* Treatment with an ARB or ACE inhibitor
* eGFR ≥ 30 mL/min/1.73 m2 and \< 60 mL/min/1.73 m2

Exclusion Criteria:

* Secondary hypertension or malignant hypertension
* Diabetes mellitus with albuminuria
* Subjects under Insulin treatment
* Subjects under or pre-planned for hemodialysis
* Serum potassium level \< 3.5 or ≥ 4.8 mEq/L

Primary outcomes:
measure: Change from baseline in sitting systolic and diastolic blood pressure
timeFrame: Baseline to end of Week 12
Secondary outcomes:
measure: Time course of systolic and diastolic blood pressure
timeFrame: Baseline to end of Week 12
measure: Proportion of patients achieving blood pressure control
timeFrame: Baseline to end of Week 12
Other outcomes:
Locations:
city: Nagano
country: Japan
Study officials:
affiliation: Daiichi Sankyo Co., Ltd.
name: Global Clinical Leader
role: STUDY_DIRECTOR
References:
Clinical trial NCT00575887: Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Official title: Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Glioblastoma
Astrocytoma
Oligodendroglioma
Brain Tumor, Recurrent
Keywords: Temozolomide
Brain Tumor, Recurrent
Chemotherapy
Lead sponsor: Marmara University
Sponsor class: OTHER
Collaborators: name: Schering-Plough
First posted: 2007-12-18
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.


Eligibility criteria: Inclusion Criteria:

* Patient age \>18 years old
* Histopathological diagnosis of high grade glioma (anaplastic astrocytoma or anaplastic oligodendroglioma or anaplastic oligoastrocytoma or glioblastoma multiforme)
* Progression after standard dose (D1-5/28 days)temozolomide either during recurrence or adjuvant treatment approved in Magnetic Resonance imaging
* Karnofsky Performance Status scale \>/=50 (due to brain pathology)
* Adequate hematological, renal and hepatic function
* Patients willing to participate in the study and signing the informed consent

Exclusion Criteria:

* Karnofsky Performance Status scale \<50
* Female patients with pregnancy or with suspicion of pregnancy. Patients with fertility will be warned for appropriate contraception during the study
* Patients not suitable for follow-up

Primary outcomes:
measure: Progression-free Survival at 6-months
timeFrame: Until progression
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Marmara University Hospital
Study officials:
affiliation: Marmara University Hospital, Radiation Oncology Department
name: Ufuk ABACIOGLU, MD
role: STUDY_CHAIR
References:
citation: Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol. 2011 Jul;103(3):585-93. doi: 10.1007/s11060-010-0423-2. Epub 2010 Sep 29.
Clinical trial NCT07018687: Improvement of Nutritional Status in Cancer Patients and Reduction of Malnutrition
Official title: Improvement of Nutritional Status in Cancer Patients and Reduction of Malnutrition
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cancer
Lead sponsor: Médipôle Lyon-Villeurbanne
Sponsor class: OTHER
First posted: 2025-06-12
Enrollment: 306
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends assessing the nutritional status of each oncology patient early and in a multidisciplinary manner.

This assessment should take into account physical activity and should allow for the patient to be provided with nutritional goals adapted to their new needs. These recommendations aim to combat malnutrition, which sometimes leads to treatment suspension and thus a loss of opportunity for the patient.


Eligibility criteria: Inclusion Criteria:

* newly diagnosed cancer

Exclusion Criteria:

* other cancer previously diagnosed
* under 18 years old
* pregnant and breastfeeding women

Primary outcomes:
measure: weight loss
timeFrame: 1 year
Secondary outcomes:
measure: quality of life sf-36
timeFrame: 1 year
Other outcomes:
Locations:
city: Villeurbanne
country: France
facility: Médipôle Hôpital Mutualiste
Study officials:
References:
Clinical trial NCT00588887: Total Knee Replacement With Duracon® and Vanguard™ Prostheses
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Degenerative Arthritis
Osteoarthritis
Rheumatoid Arthritis
Knee Arthritis
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
Collaborators: name: New Lexington Clinic
First posted: 2008-01-09
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will include patients requiring total knee replacement.

Brief summary: The purpose of this study is to compare range of motion, Knee Society Scores, and duration of surgery for different total knee prostheses.


Eligibility criteria: Inclusion Criteria:

* Patients with painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.
* Patients requiring correction of varus, valgus, or posttraumatic deformity.
* Patients requiring correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

Exclusion Criteria:

* Patients with infection, sepsis, or osteomyelitis.

Primary outcomes:
measure: Range of motion, Knee Society Score, Duration of surgery
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: United States
facility: Biomet Orthopedics, Inc.
state: Indiana
Study officials:
References:
Clinical trial NCT00389987: Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)
Official title: A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Complicated Intra-Abdominal Infections
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2006-10-19
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.

Detailed description: Original label approved November 2001

Eligibility criteria: Inclusion Criteria:

* Male or female patients (greater or equal to 18 years of age)
* Intraoperative/Postoperative Enrollment: Upon visual confirmation of an intra-abdominal infection.
* Preoperative Enrollment: Patients may be enrolled preoperatively if they meet certain criteria

Exclusion Criteria:

* Failure to meet all inclusion criteria.
* Patients who are considered unlikely to survive the 6-8 week study period.
* Pregnant or nursing women, or fertile women not practicing adequate methods of contraception.

Primary outcomes:
measure: In microbiologically evaluable patients, ertapenem will be at least as effective as piperacillin/tazobactam at the 2-weeks post-treatment Early Follow-up Assessment.
timeFrame: 2-weeks post-treatment
Secondary outcomes:
measure: In microbiologically evaluable patients, ertapenem will be at least as effective as piperacillin/tazobactam at the 4-6 weeks post-treatment Late Follow-up Assessment.
timeFrame: 4-6 Weeks post-treatment
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt). 2007 Feb;8(1):15-28. doi: 10.1089/sur.2006.030.
Clinical trial NCT01691287: MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes
Official title: MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 1 Diabetes
Keywords: Type 1 Diabetes
Metabolic Control
Quality of Life
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2012-09-24
Enrollment: 23
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Type 1 diabetes is the most common childhood disease. Treatment of diabetes requires personal checks of blood sugar levels, injecting insulin, changing eating habits and physical exercise, which requires a real change in the life of the child \& adolescent and can cause significant damage to the quality of life as well.

Compliance to treatment is a major challenge for all patients and mostly to adolescence, which often worsen their diabetes control at that age.

The Michael Method is a unique, holistic program to develop and realize an individual's emotional, intellectual and behavioral potential, which is based on the belief that every human being can excel in every field they choose. The method was developed in 1988 by a multi-disciplinary team of professional academic in Israel. Today the Israeli education system implements the method in Junior High Schools and High Schools in diverse educational sectors. The program is taught at many other various frameworks: teachers' continuing education programs, colleges, programs run by the Ministries of Defense and Social Welfare, the National Insurance Institute, the National Electric Corporation and in many other public and private frameworks.

The proposed study is aimed to assess whether the Michael Method can be used as a tool for improving metabolic control and quality of life among uncontrolled adolescence with type 1 diabetes


Eligibility criteria: Inclusion Criteria:

* Type 1 Diabetes at least 1 year prior to study inclusion
* 12-17 years old
* HbA1c \> 7.8%

Exclusion Criteria:

- Incapability to comply with all study requirements

Primary outcomes:
measure: Metabolic Control measured as HbA1c level
timeFrame: at the end of the study - after 15 weeks
Secondary outcomes:
measure: Diabetes Quality of Life questionnaire (DQOLY)
timeFrame: At the end of the study- after 15 weeks
measure: Self assessment questionnaire
timeFrame: At the end of the study- after 15 weeks
measure: Number of severe hypoglycemic events
timeFrame: at the end of the study-after 15 weeks
measure: Number of Diabetic Keto Acidosis events
timeFrame: at the end of the study- after 15 weeks
Other outcomes:
Locations:
city: Petah-TTikva
country: Israel
facility: Schneider Medical Center
Study officials:
References:
Clinical trial NCT00564187: Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
Official title: Prospective, Multicentric, Randomized, Open, Comparative Phase IV Study Evaluating the Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2007-11-27
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary:

* To evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized at 6 weeks of treatment (schema N°1: maintenance 150 mg/day, schema n°2: 300 mg/day for 6 more weeks)

Secondary:

* To evaluate the percentage of patients with DBP \< 90 mmHg at 6 and 12 weeks
* To evaluate the percentage of patients with SBP \< 140 mmHg at 6 and 12 weeks
* To evaluate rate of adverse events during the study


Eligibility criteria: Inclusion Criteria:

* Mild to Moderate hypertension (90mmHg\<DBP\<110mmHg and 140mmHg\<SBP\<180mmHg)
* Or new diagnosed hypertension (after 2 visits within 1 month), never treated before and responding to required conditions for a treatment with irbesartan, after an adapted but insufficient diet
* Or a patient having already been treated with a non-satisfying antihypertensive treatment stopped since at least 2 weeks before the inclusion
* A minimum exam labs as required by WHO-ISH within the month before the inclusion

Exclusion Criteria:

* Severe Arterial Hypertension (PAS \> than or = to 180 mm Hg or PAD \> than or = to 110 mmHg)
* Isolated Systolic Hypertension
* Secondary Hypertension
* Bilateral renal arterial stenosis or renal arterial stenosis
* Non surgically sterilised woman or non post-menopausal woman
* Confirmed sodium depletion
* Irbesartan hypersensitivity

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: To Evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized (schema N°1: maintenance 150mg/day, schema n°2: 300mg/day for 6 more weeks)
timeFrame: at 6 weeks of treatment
Secondary outcomes:
measure: • To evaluate the percentage of patients with DBP<90 mmHg
timeFrame: at 6 and 12 weeks
measure: • To evaluate rate of adverse events
timeFrame: during the study duration
measure: • To evaluate the percentage of patients with SBP<140 mmHg
timeFrame: at 6 and 12 weeks
Other outcomes:
Locations:
city: Megrine
country: Tunisia
facility: Sanofi-Aventis
Study officials:
affiliation: Sanofi
name: Chokri Jeribi
role: STUDY_DIRECTOR
References: